The 'Bio International Convention (Bio USA),' which had been suspended for in-person events due to the COVID-19 pandemic, will be held in person for the first time in three years cette année. With the global bio investissement market actuellement contrated, attention is focused on whether Korean bio companies can achieve results in technology exports, attraction d'investissements, and contrat signings.
Selon industrie sources on the 7th, more than 3,200 companies dans le monde entier are set to participate in the '2022 Bio USA,' which will be held in San Diego, USA for three days starting from the 13th (local time). Companies headquartered in Korea devraient number 255 (by corporate name). Including overseas-headquartered companies tels que NeoImmuneTech, K-bio companies are the second largest participant group after the États-Unis.
The Korea Biotechnology Industry Organization will operate the Korea Pavilion with KOTRA, introducing 12 companies notamment Standigm, Kangstem Biotech (217730), LSK Global Pharma Services, and RudaCure. A representative from the association a déclaré : "This year's Bio USA will showcase the current state of développement de nouveaux médicaments pipelines ainsi que new technologies from digital healthcare companies that developed during the COVID-19 period to the marché mondial."
Source: https://www.sedaily.com/NewsView/2675KPF54D
